LCTX / Lineage Cell Therapeutics, Inc. (LCTX) CEO Brian Culley on Q4 2021 Results - Earnings Call Transcript

Lineage Cell (LCTX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of a loss of $0.04. This compares to loss of more_horizontal

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Ioana Hone - Head of Investo more_horizontal

Penny stocks to buy have been the talk of the town in recent weeks as cyclical assets have started to make a comeback this year. Penny stocks tend to more_horizontal

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q4 2022 Earnings Conference Call March 9, 2023 4:30 PM ET Company Participants Ioana Hone - Head of IR Br more_horizontal

Lineage Cell (LCTX) delivered earnings and revenue surprises of 0% and 35.46%, respectively, for the quarter ended December 2022. Do the numbers hold more_horizontal

CARLSBAD, Calif.--( BUSINESS WIRE )--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing more_horizontal

Lineage Cell Therapeutics, Inc. (NYSE:LCTX ) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Ioana Hone - Head of I more_horizontal

Lineage Cell (LCTX) delivered earnings and revenue surprises of -33.33% and 26.97%, respectively, for the quarter ended September 2022. Do the numbers more_horizontal